BiotechTube

MenC-CRM LIQ + MenC-CRM ROS + MenC-CRM EMV

Phase 2Completed
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Meningococcal Disease

Conditions

Meningococcal Disease, Meningococcal Meningitis

Trial Timeline

Sep 1, 2011 → Nov 1, 2012

NCT ID
NCT01434680

About MenC-CRM LIQ + MenC-CRM ROS + MenC-CRM EMV

MenC-CRM LIQ + MenC-CRM ROS + MenC-CRM EMV is a phase 2 stage product being developed by Novartis for Meningococcal Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01434680. Target conditions include Meningococcal Disease, Meningococcal Meningitis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT01434680Phase 2Completed

Competing Products

20 competing products in Meningococcal Disease

See all competitors
ProductCompanyStageHype Score
RotaTeq® + NeisVac-C®MerckPhase 3
77
Meningococcal C conjugate vaccineNovartisApproved
85
Meningococcal (group B) multicomponent recombinant adsorbed vaccine. + Meningococcal (group B) multicomponent recombinant adsorbed vaccine, without Outer Membrane Vesicles (OMV)NovartisPhase 2
52
Meningococcal ACWY-CRM conjugate vaccine + Meningococcal ACWY-PS polysaccharide vaccineNovartisPhase 3
77
1a - rMenB+OMV NZ and routine vaccines + 1b - rMenB+OMV NZ and routine vaccines + 2a - Routine and rMenB+OMV NZ vaccines + 2b - rMenB+OMV NZ and routine vaccines + 3a - rMenB+OMV NZ and routine vaccines + 3b - 1 dose of rMenB+OMV NZ plus routine infant vaccinations + 4a- rMenB+OMV NZ and routine vaccines + 4b - rMenB+OMV NZ and routine vaccinesNovartisPhase 3
77
MenACWY-CRMNovartisPre-clinical
23
Meningococcal C conjugate vaccineNovartisApproved
85
Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine + MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus VaccineNovartisApproved
85
rMenB + rMenB+OMV NZNovartisPhase 2
52
Typhoid Vi Polysaccharide Vaccine + Yellow Fever Vaccine + Japanese Encephalitis Vaccine + Rabies Vaccine + MenACWY-CRM VaccineNovartisPhase 3
77
rMenB+OMV NZNovartisPhase 3
77
Meningococcal ACWY Conjugate Vaccine + DTaP-IPV-HBV + Hib + Rotavirus + Pneumococcal 7-valent Conjugate Vaccine + HAV + MMR-V + DTaPNovartisPhase 3
77
Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + Meningococcal (group B) multicomponent recombinant adsorbed vaccine + TdapNovartisPhase 2
52
MenACWY-CRMNovartisPhase 3
77
rMenB + rMenB+OMVNovartisPhase 2
52
Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV. + Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV. + Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine. + Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.NovartisPhase 2
52
MenABCWY+OMV + MenABCWY+¼OMV + PlaceboNovartisPhase 2
52
Novartis MenACWY-CRM + Saline PlaceboNovartisPhase 3
77
rMenB+OMV NZ + PlaceboNovartisPhase 2/3
65
rMenB + OMV NZ vaccine + rMenB + OMV NZ vaccine + rMenB + OMV NZ vaccine + rMenB + OMV NZ vaccine + Meningococcal C oligosaccharide conjugated vaccine + Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed. + rMenB + OMV NZ vaccine + rMenB + OMV NZ vaccineNovartisPhase 3
77

Other Products from Novartis

LCZ696Approved
85
zoledronic acidApproved
85
NateglinideApproved
85
TenofovirApproved
85
FTY720Approved
85